The FDA released its briefing documents in advance of the Peripheral and Central Nervous System Drugs Advisory Committee meeting Nov. 13. The committee will discuss the supplemental biologics license application (sBLA) for Lemtrada (alemtuzumab) injection, submitted by Genzyme Corp., a Sanofi SA company, for use in multiple sclerosis (MS).